External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology IGCS 2024
Roche and Genentech at

IGCS 2024

October 16 - October 18
Dublin, Ireland
igcs.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
02:00 PM
Duration 75mins Dublin, Ireland
Clinical outcomes with trastuzumab emtansine (T-DM1) or ipatasertib plus paclitaxel for persistent/recurrent rare epithelial ovarian cancer: ENGOT-GYN2/GOG-3051/BOUQUET phase 2 biomarker-directed study
Gershenson D, Redondo A, De La Motte Rouge T, Miller R, Brown J, Pignata S, Ayhan A, Harter P, Labidi-Galy SI, Pardo B, Kalbacher E, Kim J-W, Gourley C, Coleman RL, Manso Sanchez LM, Berton D, Malpica A, Yauch L, Dieterich M, Calas-Zeroug O, Krishnan V, Lee J-L, O'Malley D, Ray-Coquard I
Oncology | Ovarian Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.